|
Michael Newman has carried out drug discovery and early development targeting kinases, phosphatases, transporters, angiogenesis, apoptosis, transcription factors, chromatin modifications and three-dimensional cellular phenotypes. He was most recently Chief Scientific Officer and VP Research at Dihedron Corp., which invented a novel bifunctional conjugate approach for the selective targeting of cytotoxic drugs used in oncology and inflammation. Prior to Dihedron, Dr. Newman was VP of Biology at Ontogen Corporation. Before joining Ontogen, he was Executive Director of Oncology and Head of Cancer Biology in the U.S. for Novartis Pharmaceuticals, and Senior Associate Director of Preclinical Oncology and world-wide head of cancer biology at Sandoz Pharmaceuticals. Dr. Newman was a member of the faculty of The Roche Institute of Molecular Biology, and was also an American Cancer Society sponsored Assistant Professor of Biochemistry at Brandeis University. He was a Postdoctoral Fellow at Cornell University, obtained his Ph.D. in Cell and Developmental Biology at the Harvard Medical School, and received a B.A. in Biology from the University of California at San Diego. | 